Home > Insider Trading > Filing (0001209191-21-041944)

Filing Details

Accession Number:: 0001209191-21-041944
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-06-21 16:06:01
Reporting Period:: 2021-06-17

Accepted Time:: 2021-06-21 16:06:01
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1808158	Repare Therapeutics Inc.	RPTX	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1134655	Ansbert Gadicke	C/O Mpm Capital 450 Kendall Street Cambridge MA 02142		No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Shares	Disposition	2021-06-17	30,810	$33.78	4,045,958	No	4	S	Indirect	See Footnote
Common Shares	Disposition	2021-06-17	1,708	$34.12	4,044,250	No	4	S	Indirect	See Footnote
Common Shares	Disposition	2021-06-18	5,801	$33.46	4,038,449	No	4	S	Indirect	See Footnote
Common Shares	Disposition	2021-06-18	3,199	$34.03	4,035,250	No	4	S	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote

Footnotes

Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/31/2021.
The shares were sold as follows: 13,123 by MPM BioVentures 2014, L.P. ("BV 2014"), 452 by MPM Asset Management Investors BV2014 LLC ("AM BV2014") and 17,235 by UBS Oncology Impact Fund L.P. ("UBS Oncology").
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.06 to $34.03 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The shares are held as follows: 2,106,322 by BV 2014, 135,843 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 72,500 by AM BV2014 and 1,731,293 by UBS Oncology. MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. Ansbert Gadicke is a managing director of BV LLC. MPM Oncology Impact Management GP LLC ("Oncology GP LLC") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology Impact Fund, L.P. Ansbert Gadicke is the Managing Member of Oncology GP LLC. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
The shares were sold as follows: 728 by BV 2014, 25 by AM BV2014 and 955 by UBS Oncology.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.07 to $34.26 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The shares are held as follows: 2,105,594 by BV 2014, 135,843 by BV 2014(B), 72,475 by AM BV2014 and 1,730,338 by UBS Oncology. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
The shares were sold as follows: 2,471 by BV 2014, 85 by AM BV2014 and 3,245 by UBS Oncology.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.95 to $33.94 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The shares are held as follows: 2,103,123 by BV 2014, 135,843 by BV 2014(B), 72,390 by AM BV2014 and 1,727,093 by UBS Oncology. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
The shares were sold as follows: 1,363 by BV 2014, 47 by AM BV2014 and 1,789 by UBS Oncology.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.97 to $34.14 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The shares are held as follows: 2,101,760 by BV 2014, 135,843 by BV 2014(B), 72,343 by AM BV2014 and 1,725,304 by UBS Oncology. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.